Application of interleukin 19 in preparation of antiviral drugs

By studying interleukin 19 (IL-19) and its signaling pathway, it verifies its antiviral effect in vitro and in vivo, and solves the problem that existing antiviral drugs have limited protection effects on multiple viruses, and realizes IL-19 in viral infection Early effective inhibition provides new antiviral treatment methods.

CN118976101APending Publication Date: 2024-11-19SUN YAT SEN UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411069348.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The broad-spectrum protection effect of existing antiviral drugs on multiple viruses is limited, and the mechanism of action of interleukin 19 (IL-19) in the viral infection mechanism is unclear, and its potential antiviral function is not fully utilized.

Method used

By studying interleukin 19 (IL-19) and its signaling pathway, especially the IL-20RB/STAT3 pathway, it verifies its inhibitory effect on viral infection in vitro and in vivo, and develops a new application of IL-19 as an antiviral drug. Transcriptomics and animal models validate its antiviral effects.

Benefits of technology

IL-19 significantly inhibits viral replication by regulating the host's natural immune system, providing new antiviral treatment methods, especially effective in the early stages of viral infection, supplementing the shortcomings of existing clinical antiviral treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004980379080000011
    Figure HDA0004980379080000011
  • Figure HDA0004980379080000012
    Figure HDA0004980379080000012
  • Figure HDA0004980379080000021
    Figure HDA0004980379080000021
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, and particularly relates to application of interleukin 19 in preparation of antiviral drugs. The invention discovers the application of IL-19 in preparation of antiviral products for the first time. The invention finds that IL-19 has new functions of regulating and controlling a host innate immune system and playing a broad-spectrum antiviral role; the molecular mechanism of the antiviral effect of IL-19 is deeply clarified, and a theoretical basis is provided for a targeted IL-19 signal channel as an antiviral treatment method; animal experiments prove that in the early stage of virus infection, continuous intraperitoneal injection of IL-19 protein can effectively inhibit virus replication level, and IL-19 recombinant protein is expected to be used as an antiviral biological preparation to supplement an effective method for current clinical antiviral treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to the application of interleukin 19 in the preparation of antiviral drugs. Background Art

[0002] Viruses have always been one of the main pathogens that endanger human health, and new and emerging viral infectious diseases are a major public health problem facing mankind. Among them, highly effective and broad-spectrum antiviral drugs have always been an urgent need for the prevention and treatment of viral infections in clinical practice, and are also a long-term research hotspot and pursuit goal in the medical community. Immunomodulators are one of the research directions of antiviral drugs, especially regulators targeting the host's natural immune system. Interferon is a secreted glycoprotein that plays a key role in the natural immune system. It exerts a broad-spectrum antiviral effect by inducing the expression of various interferon-stimulated genes (ISGs) and is the target of many immunomodulators.

[0003] Interleukins are the first type of cytokines discovered and named. Previous studies have found that certain interleukins (IL) directly or indirectly regulate interferon-related signaling pathways through the cytokine regulatory network, exerting antiviral or proviral effects. Studies have found that IL-1β activates the cGAS-STING pathway by promoting the release of mitochondrial DNA, exerting an anti-dengue virus effect; IL-3 can induce the secretion of CXCL12, thereby promoting the secretion of IFNα and IFNλ by plasmacytoid dendritic cells, exerting an anti-HSV-1 effect; IL-27 can exert an anti-hepatitis B virus effect by upregulating TRIM25, and can also regulate CD4 + The function of T cells plays an anti-HIV role; IL-36 promotes the effect of interferon by upregulating type I interferon receptors, thereby playing an anti-HSV-1 role.

[0004] IL-19 is a cytokine present in the human body and is a member of the IL-20 subfamily. IL-19 binds to the receptor complex IL-20RB and induces conformational changes in the receptor protein on the cell membrane, followed by the recruitment of the IL-20RA chain to activate the Janus family kinase and signal transducer transcription activator (STAT) pathway. The regulatory effect of IL-19 on the immune system has been widely recognized. IL-19 has been shown to be involved in the pathogenesis of immune system diseases such as asthma, rheumatoid arthritis, psoriasis, and atopic dermatitis. IL-19 also plays a role in the occurrence and development of infectious diseases. The IL-19 gene polymorphism in the population is associated with the infection and progression of HIV and HBV. Other studies have found that IL-19 can regulate the expression of Th1 / Tc1 and Th17 / Tc17 in CD4 + and CD8 +T cells play a certain protective role in the process of tuberculosis infection. However, the mechanism of how IL-19 affects viral infection is still unclear, and whether IL-19 can be used as an antiviral immunomodulator is still unclear. Summary of the invention

[0005] The purpose of the first aspect of the present invention is to provide an application.

[0006] The second aspect of the present invention aims to provide a composition.

[0007] The second aspect of the present invention aims to provide a method for inhibiting viral proliferation in cells in vitro for non-therapeutic purposes.

[0008] In order to achieve the above-mentioned purpose of the present invention, the technical solution adopted by the present invention is:

[0009] The first aspect of the present invention provides the use of a1) to a3) in the preparation of antiviral products

[0010] a1) Interleukin 19 or its derivatives

[0011] a2) Biological materials related to interleukin 19;

[0012] a3) Function enhancer of interleukin-19.

[0013] The number of interleukin 19 in the NCBI database is NM_001369605.1.

[0014] The amino acid sequence of interleukin 19 is: MKLQCVSLWLLGTILILCSVDNHGLRRCLISTDM HHIEESFQEIKRAIQAKDTFPNVTILSTLETLQIIKPLDVCCVTKNLLAFYVDRVFKDHQEPNP KILRKISSIANSFLYMQKTLRQCQEQRQCHCRQEATNATRVIHDNYDQLEVHAAAIKSLGEL DVFLAWINKNHEVMFSA (SEQ ID NO: 1).

[0015] Preferably, the derivative comprises at least one of b1) to b3):

[0016] b1) pharmaceutically acceptable salts;

[0017] b2) a polypeptide having one or more amino acids added, deleted, or substituted with SEQ ID NO: 1, wherein the polypeptide has a function close to that of interleukin 19;

[0018] b3) pharmaceutically acceptable modified forms.

[0019] Preferably, the pharmaceutically acceptable salt includes at least one of a metal salt, an ammonium salt, a salt formed with an inorganic acid, a salt formed with an organic base, a salt formed with an organic acid, a salt formed with a basic amino acid, and a salt formed with an acidic amino acid.

[0020] Preferably, the metal salt comprises an alkali metal salt or an alkaline earth metal salt.

[0021] Preferably, the alkali metal salt includes at least one of a sodium salt and a potassium salt.

[0022] Preferably, the alkaline earth metal salt includes at least one of calcium salt, magnesium salt, barium salt and aluminum salt.

[0023] Preferably, the salt formed with the organic base includes a salt formed with the following organic bases: at least one of trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine and N,N'-dibenzylethylenediamine.

[0024] Preferably, the salt formed with an inorganic acid includes a salt formed with the following inorganic acids: at least one of hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, and phosphoric acid.

[0025] Preferably, the salt formed with the organic acid includes a salt formed with the following organic acids: at least one of formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid.

[0026] Preferably, the salt formed with a basic amino acid comprises a salt formed with the following basic amino acids: at least one of arginine, lysine and ornithine.

[0027] Preferably, the salt formed with the acidic amino acid includes a salt formed with the following acidic amino acids: at least one of aspartic acid and glutamic acid.

[0028] Preferably, the pharmaceutically acceptable modification comprises at least one of phosphorylation, acylation, glycosylation, ubiquitination, acetylation, methylation, sulfation, and phospholipidation.

[0029] Preferably, the interleukin-related biological material comprises at least one of c1) to c4):

[0030] c1) a nucleic acid molecule encoding the interleukin 19 according to claim 1;

[0031] c2) an expression cassette containing the nucleic acid molecule described in c1);

[0032] c3) a vector containing the nucleic acid molecule described in c2);

[0033] c4) A cell line containing the nucleic acid molecule described in c3).

[0034] In some embodiments of the present invention, the interleukin-related biological material includes pCDNA3.1-IL19.

[0035] Preferably, the interleukin-19 function promoter includes at least one of IL20RB and STAT3.

[0036] Preferably, the amino acid sequence of IL2ORB is MQTFTMVLEEIWTSLFMWFFYALIPC LLTDEVAILPAPQNLSVLSTNMKHLLMWSPVIAPGETVYYSVEYQGEYESLYTSHIWIPSSWCSLTEGPECDVTDDITATVPYNLRVRATLGSQTSAWSILKHPFNRNSTILTRPGMEITKDGFHLVIELEDLGPQFEFLVAYW RREPGAEEHVKMVRSGGIPVHLETMEPGAAYCVKAQTFVKAIGRYSAFSQTECVEVQGEAIPLVLALFAFVGFMLILVVVPLFVWKMGRLLQYSCCPVVVLPDTLKITNSPQKLISCRREEVDACATAVMSPEELLRAWIS(SEQ ID NO: 2).

[0037] Preferably, the amino acid sequence of STAT3 is MAQWNQLQQLDTRYLEQLHQLYSDSF (SEQ ID NO: 3).

[0038] Preferably, the virus comprises at least one of herpes simplex virus, influenza A virus, Zika virus, and vesicular stomatitis virus.

[0039] Preferably, the virus comprises herpes simplex virus; further preferably, it is herpes simplex virus type 1.

[0040] Preferably, the herpes simplex virus comprises HSV-1 McKrae strain.

[0041] The second aspect of the present invention provides a composition comprising at least one of IL20RB and STAT3 according to the first aspect of the present invention, and interleukin-19.

[0042] Preferably, the composition may also include other antiviral drugs.

[0043] Preferably, the composition further comprises a pharmaceutically acceptable excipient.

[0044] Preferably, the pharmaceutically acceptable excipients include at least one of a stabilizer, an antioxidant, a pH adjuster, a preservative, and an antibacterial agent.

[0045] The third aspect of the present invention provides a method for inhibiting viral proliferation in cells in vitro for non-therapeutic purposes, wherein the cells are treated with a1) to a3) described in the first aspect of the present invention and / or the composition of the second aspect of the present invention.

[0046] a1) Interleukin 19 or its derivatives

[0047] a2) Biological materials related to interleukin 19;

[0048] a3) Function enhancer of interleukin-19.

[0049] Preferably, the virus comprises at least one of herpes simplex virus, influenza A virus, Zika virus, and vesicular stomatitis virus.

[0050] Preferably, the virus comprises herpes simplex virus; further preferably, it is herpes simplex virus type 1.

[0051] Preferably, the cells comprise A549 cells.

[0052] The beneficial effects of the present invention are:

[0053] The present invention discovers for the first time the application of IL-19 in the preparation of therapeutic antiviral products. First, the effect of IL-19 on viral infection was identified in an in vitro test, and the mechanism was verified whether the antiviral effect of IL-19 was through the IL20RB / STAT3 signaling pathway. Subsequently, the antiviral functional genes regulated by IL-19 were screened by transcriptomics methods to verify the effect of IL-19 on these antiviral functional genes. Finally, through a mouse virus infection model, it was proved that intraperitoneal injection of IL-19 can effectively inhibit HSV-1 infection in mice. The present invention newly discovered that IL-19 has a new function of regulating the host's natural immune system and exerting a broad-spectrum antiviral effect; the molecular mechanism of IL-19's antiviral effect was deeply explained, and a theoretical basis for targeting the IL-19 signaling pathway as an antiviral treatment method was provided; animal experiments proved that in the early stage of viral infection, continuous intraperitoneal injection of IL-19 protein can effectively inhibit the level of viral replication, and it is expected to use IL-19 recombinant protein as an antiviral biological agent to supplement the current effective methods of clinical antiviral treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] Figure 1 This is the identification of the broad-spectrum antiviral effect of IL-19, where A, B, C, and D are the results of LI-19's inhibition of HSV-UL27, IAV, ZIKV, and VSV virus proliferation; E and F are the results of transcriptomic analysis of A549 cells after IL-19 overexpression.

[0055] Figure 2 These are the experimental results showing that the antiviral effect of IL-19 depends on IL20RB, where A is the Western Blot experimental result; B is the effect of IL-19 on the proliferation of HSV-UL27 in A549 cells; C is the effect of IL-19 on the proliferation of HSV-UL27 in 293T cells.

[0056] Figure 3 These are the experimental results showing that the antiviral effect of IL-19 depends on STAT3 phosphorylation, where A is the Western Blot experimental result; B is the effect of IL-19 on the proliferation of HSV-UL27 after A549 cells were treated with the STAT3 phosphorylation inhibitor WP1066.

[0057] Figure 4 These are the screening results of antiviral factors downstream of the IL-19 signaling pathway, where A is the volcano plot result of differentially expressed genes; B and C are the changes of TRIM22 and IFNλ after IL-19 treatment.

[0058] Figure 5These are the results of identification of antiviral factors downstream of the IL-19 signaling pathway, where A is the effect of TRIM22 on HSV-UL27 proliferation; B is the experimental result of Western Blot detection of protein expression; and C is the effect of TRIM22 on IFNλ levels.

[0059] Figure 6 Schematic diagram of the model for medication and virus attack in mice.

[0060] Figure 7 The figure shows the overall protective effect of IL-19 on mice, where A is the weight change of mice; B is the overall survival rate of mice; and C is the actual photo of the symptoms of periocular herpetic keratitis in mice.

[0061] Figure 8 The results show that IL-19 can inhibit viral replication and upregulate IFNλ, where A and B are the results of HSV-27 proliferation changes in the brain and lung tissues; C is the result of virus titer in bronchoalveolar lavage fluid; D and E are the results of IFNλ level changes in the brain and lung tissues; F is the result of IFNλ level changes in bronchoalveolar lavage fluid. DETAILED DESCRIPTION

[0062] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0063] Example 1 IL-19 has broad-spectrum antiviral function

[0064] 1. Experimental methods

[0065] 1) Virus proliferation detection

[0066] The IL-19 plasmid is pCDNA3.1-IL19. The IL-19 sequence (NCBI: NM_001369605.1) was successfully cloned into the mammalian expression vector pCDNA3.1 empty plasmid (Empty) after amplification, restriction digestion, ligation, and transformation according to the fourth edition of the Molecular Cloning Experiment Guide.

[0067] After overexpressing 0, 1.0 μg, and 2.0 μg of IL-19 plasmid in A549 cells for 24 hours, viruses were added to infect the cells. The viruses included herpes simplex virus type 1 (HSV-1), influenza A virus (IAV), Zika virus (ZIKV), and vesicular stomatitis virus (VSV). A total of 12 experiments were conducted with 3 plasmid concentrations and 4 viruses.

[0068] Among them, the multiplicity of infection (MOI) of HSV-1 was 0.5, and total cell RNA was extracted 12 hours after infection; the MOI of IAV was 1.0, and total cell RNA was extracted 24 hours after infection; the MOI of ZIKV was 1.0, and total cell RNA was extracted 12 hours after infection; the MOI of VSV was 1.0, and total cell RNA was extracted 12 hours after infection.

[0069] Real-time fluorescence quantitative PCR was used to detect the nucleic acid replication level of each virus. HSV primer sequence: HSV-1UL27 Forward: GCCTTCTTCGCCTTTCGC (SEQ ID NO: 4), Reverse: CGCTGTGCCCTTCTTCTT (SEQ ID NO: 5); IAV primer sequence: Forward: AGGACAAGAGCTCTTGTTCG (SEQ ID NO: 6), Reverse: CTCTTGTGTGCTGGATTCT (SEQ ID NO: 7); ZIKV primer sequence: Forward: GGTCAGCGTCCTCTCTAATAAACG (SEQ ID NO: 8), Reverse: GCACCCTAGTGTCCACTTTTTCC (SEQ ID NO: 9); VSV primer sequence: Forward: GAAAGGGAACTGTGGGATGA (SEQ ID NO: 10), Reverse: GAACACCTGAGCCTTTGAGC (SEQ ID NO: 11), the kits used included: Cell RNA Rapid Extraction Kit (EZBioscience, B0004D), Ⅲ1st Strand cDNA Synthesis SuperMix for qPCR (Yeasen, 11141ES60), qPCR Green Master Mix(Yeasen, 11202ES08)

[0070] The HSV-1 used in this example was stored in this laboratory, VSV was kindly donated by Dr. Lan Tian of VectorBuilder, ZIKV was kindly donated by Associate Professor Luo Huanle of the School of Public Health (Shenzhen) of Sun Yat-sen University, and IAV was kindly donated by Professor Shu Yuelong of the School of Public Health (Shenzhen) of Sun Yat-sen University. The pathogens used in the present invention have been published in public journals (doi: 10.1371 / journal.ppat.1010366) and are openly accessible. The relevant experiments were carried out in a P2 biosafety standard laboratory with relevant permission.

[0071] 2) Transcriptomic analysis

[0072] After overexpressing 2 μg of IL-19 plasmid in A549 cells, HSV-1 virus was added at MOI = 0.5. After 1 and 12 hours of infection, total cellular RNA was extracted and handed over to Beijing Qingke Biotechnology Co., Ltd. to generate RNA-seq library and detect it using TruSeq PE Cluster Kitv4cBot HS (Illumina, USA).

[0073] 2. Experimental results

[0074] The results of nucleic acid replication level detection of each virus are as follows Figure 1 As shown in A, B, C, and D. As IL-19 expression increased, the replication levels of all viruses decreased, especially HSV-1 and VSV.

[0075] The transcriptomic analysis results are as follows Figure 1 As shown in E and F, signaling pathways and functional genes related to multiple viral infections were enriched after overexpression of IL-19.

[0076] Example 2 The role of IL-19 receptor IL20RB and its downstream transcription factor STAT3 in the antiviral process of IL-19

[0077] First, this example tested the expression results of IL20RB and STAT3 in A549 and 293T cells. The Western Blot experimental results are shown in Figure 2. Figure 2 As shown in A. A549 cells can normally express IL20RB and STAT3, while 293T cells can express STAT3 but not IL20RB.

[0078] Secondly, A549 cells and 293T cells were incubated with recombinant IL-19 protein (MCE, catalog number: HY-P7212) (three concentrations were set, 0, 100, and 200 ng / mL, respectively) for 12 hours, and HSV-1 virus was added at MOI = 0.5. After infecting A549 cells for 12 hours, total cell RNA was extracted, and real-time fluorescence quantitative PCR was used to detect the level of HSV-1 nucleic acid replication. Related methods and materials refer to Example 1.

[0079] The results are as follows Figure 2 As shown in B and C. In A549 cells with IL20RB, IL-19 protein can inhibit viral proliferation, but in 293T cells deficient in IL20RB, IL-19 protein has no antiviral effect, proving that IL20RB is critical for IL-19 to exert its antiviral effect.

[0080] Finally, 12 hours after A549 cells were transfected with 2.0 μg IL-19 plasmid, 2.0 μM / mL of STAT3 inhibitor WP1066 (GLPBIO, Catalog No.: GC15980) was added to the cell culture medium. After incubation for 12 hours, HSV-1 virus was added at MOI = 0.5. Total RNA was extracted from A549 cells 12 hours after infection, and the level of HSV-1 nucleic acid replication was detected by real-time fluorescence quantitative PCR. The results are shown in Figure 3 As shown, after STAT3 inhibition, the antiviral effect of IL-19 was weakened, proving that STAT3 phosphorylation plays a key role in the antiviral process of IL-19.

[0081] Example 3 Screening and identification of antiviral factors downstream of IL-19 signaling pathway

[0082] After overexpressing 2.0 μg of IL-19 plasmid in A549 cells for 24 hours, HSV-1 virus was added at an MOI of 0.5, and total cellular RNA was extracted 12 hours after infection of A549 cells for transcriptomic analysis.

[0083] The differentially expressed genes (DEGs) were screened out using FDR < 0.05 and |log2FC| > 1 as the screening criteria, and the DEGs were plotted into a volcano plot to screen the top 10 DEGs with the smallest FDR. Figure 4 As shown in A, ten genes including TRIM22, IFITM1, IFI27, IFIT2, ISG20, LAMP3, TNFSF10, BOLA2, CASP1, and IFNL1 (IFNλ) were screened. Among them, TRIM22 and IFNλ were selected for further analysis.

[0084] A549 cells were transfected with 2.0 μg pCDNA3.1-Empty or pCDNA3.1-IL19 for 24 h, and then infected with HSV-1 (MOI = 0.5) for 12 h in the presence or absence of WP1066 (2.0 μM / ml). qPCR analysis showed that the upregulation of TRIM22 and IFNλ by overexpression of IL-19 was attenuated (results shown in Figure 4 (as shown in B and C). TRIM22 primer sequence: Forward: CTGTCCTGTGTGTCAGACCAG (SEQ ID NO: 12), Reverse: TGTGGGCTCATCTTGACCTCT (SEQ ID NO: 13); IFNλ primer sequence: Forward: GGTGACTTTGGTGCTAGGCT (SEQ ID NO: 14), Reverse: TGAGTGACTCTTCCAAGGCG (SEQ ID NO: 15).

[0085] In A549 cells, 1.0 μg and 2.0 μg of TRIM22 plasmid were transfected for 24 hours, and HSV-1 virus was added at MOI = 0.5. Total RNA was extracted from A549 cells after infection for 12 hours, and real-time fluorescence quantitative PCR and Western Blot were used to detect HSV-1 nucleic acid replication and viral protein expression levels. Figure 5 As shown in A to B, TRIM22 can effectively inhibit HSV-1 nucleic acid replication and protein expression. Real-time fluorescence quantitative PCR detection found that overexpression of TRIM22 can effectively upregulate the level of IFNλ (results are shown in Figure 5 (as shown in C).

[0086] The TRIM22 plasmid is pCDNA3.1-TRIM22. The TRIM22 sequence (NCBI: NM_001199573.2) was successfully cloned into the mammalian expression vector pCDNA3.1 empty plasmid (Empty) after amplification, restriction digestion, ligation and transformation according to the fourth edition of the Molecular Cloning Experiment Guide.

[0087] Example 4 IL-19 has antiviral effects at the animal level

[0088] 1. Experimental methods

[0089] 1) Mouse IL-19 administration model and challenge

[0090] SPF C57BL / 6 mice were randomly divided into three groups: a. blank control group (n=5); b. PBS treatment group (n=12); c. IL19 treatment group (n=12). There was no significant difference in body weight among the groups. Blank control group: sterile PBS solution was injected intraperitoneally from three days before nasal drip treatment to the first day after nasal drip treatment (five consecutive days); PBS treatment group: sterile PBS solution was injected intraperitoneally from three days before nasal drip infection to the first day after infection (five consecutive days); IL19 group: mouse-derived IL-19 protein (GLPBIO, catalog number: GP20612, diluted to 2μg / mL with sterile PBS before use) was injected intraperitoneally from three days before nasal drip infection to the first day after infection (five consecutive days).

[0091] The HSV-1 nasal infection model was constructed: one operator took a fully anesthetized mouse (ensuring stable breathing), clamped the skin of the head and neck with the thumb and index finger to fix the head, turned the wrist so that the mouse's abdomen was facing the operator, and the body was stretched, the head was upward, and the body was tilted at 45° to the horizontal plane. The thumb of the other hand covered the mouse's mouth, and the index finger was bent and pressed above the mouse's nasal bone. Another operator used a pipette to draw 50uL (1×10 5PFU) of melted HSV-1 virus solution (Mock group was replaced with sterile PBS), the tip of the pipette was placed at the mouse nostril, and the virus was evenly and slowly dripped into the mouse nostril, half of the volume of virus was dripped into one nostril and then the other nostril was changed. The state changes of the mice were continuously observed from infection to the 10th day after infection, and the weight, condition and survival of the mice were recorded.

[0092] 2) Serum collection

[0093] After the mice were anesthetized by inhalation, the eyeballs were removed and blood was collected in a 1.5 mL sterile EP tube; the tube was placed at 4°C for about 1 hour; the supernatant was collected after centrifugation at 8000 rpm and 4°C for 10 min, and stored in aliquots at -80°C.

[0094] 3) Bronchoalveolar lavage fluid (BALF) collection

[0095] After the mouse was euthanized, the mouse was fixed (a rope was put through the teeth to fix the head), and the mouse's trachea was exposed by dissection; the line was passed under the trachea, a small incision was made on the trachea, and a sterile 22G indwelling needle was inserted (<0.8mm, the needle tip was blunted before being inserted into the mouse arteriovenous catheter to prevent puncturing the trachea), and the trachea and the inserted needle were tied tightly; 0.5mL of pre-cooled sterile PBS was slowly injected into the lungs with a syringe (the lungs could be seen to bulge), and the lungs were gently pressed a few times, and PBS was withdrawn after 15-30s. Repeat the operation, wash 3 times in total, and recover about 1.2mL of lavage fluid in total; the lavage fluid was centrifuged at 2000rpm and 4℃ for 10 minutes, and the supernatant was aliquoted and stored at -20℃.

[0096] 4) Brain and lung RNA extraction

[0097] (1) Dissect and separate the brain and lung of mice; (2) Cut about 50 mg of tissue into an EP tube, use a tissue RNA extraction kit (Novozyme, catalog number R711-01), add 500 μL FreeZol Reagen, and add 2 3 mm and 2 mm steel beads, and use a low-temperature tissue homogenizer to prepare cell homogenate; (3) Add 100 μL of Dilution Buffer in the kit, vortex and oscillate to mix thoroughly, and let stand at room temperature for 5 minutes; (4) Centrifuge at 11200 rpm at room temperature for 15 minutes; (5) Carefully pipette the supernatant (about 500 μL) into a new EP tube; (6) Add an equal volume of isopropanol to the supernatant solution, mix thoroughly by inverting, and let stand at room temperature for 10 minutes; (7) Centrifuge at 11200 rpm at room temperature for 10 minutes, and carefully discard the supernatant; 8) Add 1 mL 75% ethanol, flick the bottom of the tube and invert it several times; (9) Centrifuge at 9100 rpm for 3 min at room temperature and carefully discard the supernatant; (10) Repeat steps (8) and (9), and use a pipette to remove as much remaining liquid as possible; 11) Let it dry at room temperature, add 100 μL RNase-free ddH2O to dissolve the precipitate, vortex at room temperature for 3 min to fully dissolve the RNA precipitate, detect the concentration, and conduct subsequent experiments.

[0098] 5) ELISA

[0099] (1) Set up standard wells and add different concentrations of standard wells from low to high, 50 μL per well; (2) Set up several sample wells, add 10 μL of the sample to be tested (serum / BALF) to each well, and then add 40 μL of sample diluent; (3) Set up 1 blank well. In addition to the blank well, add 100 μL of horseradish peroxidase (HRP)-labeled detection antibody to each well of the standard well and sample well, affix sealing film, and incubate in a 37°C incubator for 60 min; 4) Discard the liquid, pat dry on absorbent paper, add 200 μL of washing solution to each well, and incubate. Leave for 1 minute, shake off the washing solution, pat dry on absorbent paper, and repeat 5 times; (5) Add 50 μL of substrate A and B to each well, and incubate in a 37°C thermostat in the dark for 15 minutes; (6) Add 50 μL of stop solution to each well, and measure the OD value of each well at a wavelength of 450 nm within 15 minutes; (7) Calculate the standard curve based on the OD value and concentration of the standard well, and calculate the concentration of the sample well according to the standard curve formula by substituting the OD value of the blank well into the OD value of each well (the OD value of each well is calculated after subtracting the OD value of the blank well, and the final calculated concentration is the concentration of the sample after 5 times dilution). (The kit model used for mouse IL-19 detection is: ELISA, catalog number: MM-45493M2; the kit model used for mouse IFN-λ detection is: ELISA, catalog number: MM-44821M1)

[0100] 6) Virus titer determination

[0101] (1) Cell plating: Vero cell suspension at 2×10 4 Cells / well were plated into 96-well cell culture plates and cultured until the cells were confluent to about 90%; (2) Gradient dilution of the sample to be tested: After the alveolar lavage fluid was filtered through a 0.45 μm sterilizing filter, it was diluted tenfold using serum-free DMEM medium, generally 10 -1 ~10 -8 There are 8 gradients in total; (3) Aspirate and discard the old culture medium of Vero cells in the 96-well plate, add 100 μL of the gradient diluted bronchoalveolar lavage fluid to each well, and set up 8 replicate wells for each gradient; set up a column of negative control wells on each plate, and only add 100 μL of serum-free DMEM for culture; (4) Culture in a cell culture incubator for 3 to 5 days, observe the cytopathic effect, and record the number of wells with cytopathic effect (CPE) in each gradient; (5) Calculate TCID 50 : The cell culture median infectious dose was calculated by the Karber method.

[0102] 7) Observation of brain and lung pathological sections

[0103] After the mouse tissues were completely immersed in 4wt% paraformaldehyde for fixation, they were then embedded in paraffin, sliced, stained, decolorized, and sealed to prepare pathological sections. Finally, the qualified samples were prepared for microscopic examination. Hematoxylin and eosin (H&E) staining was performed by dewaxing, hydration, hematoxylin staining, color separation, and eosin counterstaining, and images were collected using an upright white light camera microscope.

[0104] 2. Experimental results

[0105] The overall protective effect of IL-19 on mice Figure 7 As shown, after IL-19 administration, the weight loss of mice in the early stage of viral infection was slowed down, the symptoms of herpetic keratitis were alleviated, and there was a certain protective trend in the overall survival rate.

[0106] Viral replication in IL-19 treated mice Figure 8 As shown in Figure 2, IL-19 administration can effectively inhibit viral replication in the brain and lungs, and significantly induce the expression of IFNλ.

[0107] In summary, IL-19 has a new function of regulating the host's natural immune system and exerting a broad-spectrum antiviral effect. It can be used as an antiviral immunomodulator for antiviral treatment.

Claims

1. Application of a1) to a3) in the preparation of antiviral products: a1) interleukin 19 or its derivatives; a2) Biological materials related to interleukin 19; a3) interleukin-19 function enhancer; The amino acid sequence of interleukin 19 is shown in SEQ ID NO:

1.

2. The use according to claim 1, characterized in that: The derivatives include at least one of b1) to b3): b1) pharmaceutically acceptable salts; b2) a polypeptide having one or more amino acids added, deleted, or substituted with SEQ ID NO: 1, wherein the polypeptide has a function close to that of interleukin 19; b3) pharmaceutically acceptable modified forms.

3. The use according to claim 2, characterized in that: The pharmaceutically acceptable salt includes at least one of a metal salt, an ammonium salt, a salt formed with an inorganic acid, a salt formed with an organic base, a salt formed with an organic acid, a salt formed with a basic amino acid, and a salt formed with an acidic amino acid; or The pharmaceutically acceptable modification comprises at least one of phosphorylation, acylation, glycosylation, ubiquitination, acetylation, methylation, sulfation, and phospholipidation.

4. The use according to claim 1, characterized in that: The interleukin-related biological material includes at least one of c1) to c4): c1) a nucleic acid molecule encoding the interleukin 19 according to claim 1; c2) an expression cassette containing the nucleic acid molecule described in c1); c3) a vector containing the nucleic acid molecule described in c2); c4) A cell line containing the nucleic acid molecule described in c3).

5. The use according to claim 1, characterized in that: The interleukin-19 function promoter includes substances that increase the expression of interleukin-19 and the activity of interleukin-19.

6. The use according to claim 5, characterized in that: The interleukin-19 function promoter includes at least one of IL20RB and STAT3.

7. The use according to any one of claims 1 to 6, characterized in that: The virus includes at least one of herpes simplex virus, influenza A virus, Zika virus, and vesicular stomatitis virus; Preferably, the virus comprises herpes simplex virus; Preferably, the herpes simplex virus comprises HSV-1 McKrae strain.

8. A composition comprising interleukin 19 and other antiviral drugs.

9. The composition according to claim 8, characterized in that: The composition further comprises a pharmaceutically acceptable excipient; Preferably, the pharmaceutically acceptable excipients include at least one of a stabilizer, an antioxidant, a pH adjuster, a preservative, and an antibacterial agent.

10. A method for inhibiting viral proliferation in cells in vitro for non-therapeutic purposes, comprising treating the cells with a1) to a3) as described in any one of claims 1 to 7, and / or the composition as described in any one of claims 8 to 9; Preferably, the virus comprises at least one of herpes simplex virus, influenza A virus, Zika virus, and vesicular stomatitis virus.